SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

AUSTEDO

TEVA·TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market, first approved April 2017; Austedo XR approved February 2023
Why 4/10
Austedo is already approved and commercially marketed with no pending binary catalyst (PDUFA or pivotal readout) in the next ~12 months. Per the impact score rubric, an approved drug with no imminent new regulatory decision scores 3-5, the binary events (initial FDA approvals in 2017, XR approval in 2023) have already passed.
Actionable Insight NEUTRAL

Austedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.

Price Chart

Loading chart...

Executive Summary

Austedo (deutetrabenazine) is Teva Pharmaceutical's already-approved, commercial-stage VMAT2 inhibitor for treating tardive dyskinesia and Huntington's disease chorea. First approved by the FDA in April 2017, with an extended-release version (Austedo XR) approved in February 2023. Austedo is Teva's largest innovative brand: H1 2026 revenue was approximately $696M, with the combined innovative brand portfolio (Austedo, Ajovy, Uzedy) growing 43% YoY in local currency. Teva raised its 2026 revenue outlook for these three brands to ~$3.7B combined. With no pending PDUFA or pivotal readout, Austedo's stock-moving binary catalyst has already passed, its value to shareholders is commercial execution and revenue growth within a diversified large-cap pharma ($16.5-16.85B total revenue, $36.9B market cap).

How It Works

Austedo is a VMAT2 inhibitor, it reduces the amount of certain chemicals (dopamine) in the brain that cause uncontrolled movements. It is a deuterated (chemically modified for slower breakdown) version of the older drug tetrabenazine, allowing for less frequent dosing and potentially fewer side effects.

Trial Status

Austedo and Austedo XR are both FDA-approved and commercially available. The pivotal trials (ARM-TD for tardive dyskinesia, FIRST-HD for Huntington's chorea) completed years ago. No active pivotal-stage trials for new indications were found in the SecBot database.

The Two-Sided Case

▲ Bull Case5
Austedo is Teva's largest innovative brand with an ~$1.4B annualized revenue run-rate based on H1 2026 figures of ~$696M, driving robust 43% LC YoY growth for the innovative brand portfolio.
Teva raised its 2026 combined revenue outlook for Austedo, Ajovy, and Uzedy to ~$3.7B, reflecting strong commercial momentum and market share gains.
Austedo XR (once-daily formulation) expands the addressable patient population with a convenience advantage over twice-daily immediate-release formulations.
Teva's June 2026 Fitch credit rating upgrade to investment-grade BBB- signals improving financial health and may enable further investment in Austedo commercialization.
Analyst consensus on TEVA is Strong Buy (6 buy/strong buy, 1 hold) with a mean price target of $41.40, implying ~12.4% upside from the $36.93 current price.
▼ Bear Case5
Austedo faces competitive pressure from Neurocrine's Ingrezza (valbenazine), the first-mover in tardive dyskinesia with a larger commercial presence and established brand recognition.
As a large-cap pharma drug within a $36.9B market-cap company, even significant Austedo revenue beats have limited single-stock impact, the drug is ~8-10% of Teva's total revenue.
Generics erosion of Teva's legacy products (U.S. generics -31% YoY in Q2 2026) and a heavy debt load ($16.6B, 68% leverage) are macro overhangs.
Insider selling in August 2026 (EVP Lippman sold $680K, CHRO Jover sold $447K under 10b5-1 plans) may signal limited near-term upside conviction from management.
Teva's Q2 2026 GAAP loss of $0.49/share and adjusted EPS miss ($0.02 vs $0.05 consensus) raise execution risk despite Austedo's strength.

Upcoming Catalysts

  • No FDA PDUFA dates or pivotal readouts scheduled for Austedo specifically; commercial revenue growth trajectory is the key ongoing metric.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K TEVA ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov